

Supplementary materials

Content

1. SEARCH FORMULAS FOR DIFFERENT DATABASES.	2
1.1 PUBMED.....	2
1.2 WEB OF SCIENCE	3
1.3 COCHRANE.....	3
1.4 EMBASE.....	4
2. BASIC CHARACTERISTICS OF INCLUDED LITERATURE.....	5
3. ASSESSMENT OF INCLUDED LITERATURE QUALITY	12
4. RISK OF BIAS.....	14
5. RESULTS	30
5.1 ANY CANCER	30
5.2 LUNG CANCER	31
5.3 BRONCHIAL CANCER.....	33
5.4 THYROID CANCER.....	34
5.5 GASTRIC CANCER.....	36
5.6 PANCREATIC CANCER.....	37
5.7 RECTAL CANCER	39
5.8 COLON CANCER	40
5.9 BLADDER CANCER	42
5.10 PROSTATE CANCER.....	43
5.11 UTERINE CANCER.....	45
5.12 BREAST CANCER	46
5.13 HEPATOCELLULAR CANCER.....	48
5.14 RENAL CANCER.....	49
5.15 HEMATOLOGIC CANCER	51

1. Search formulas for different databases.

1.1 PubMed

#1	("Diabetes Mellitus, Type 2"[Mesh]) OR (((((((((((((((((((((((((Diabetes Mellitus, Type 2[Title/Abstract])) OR (Diabetes Mellitus, Noninsulin-Dependent[Title/Abstract])) OR (Diabetes Mellitus, Ketosis-Resistant[Title/Abstract])) OR (Diabetes Mellitus, Ketosis Resistant[Title/Abstract])) OR (Ketosis-Resistant Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus, Non Insulin Dependent[Title/Abstract])) OR (Diabetes Mellitus, Non-Insulin-Dependent[Title/Abstract])) OR (Non-Insulin-Dependent Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus, Stable[Title/Abstract])) OR (Stable Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus, Type II[Title/Abstract])) OR (NIDDM[Title/Abstract])) OR (Diabetes Mellitus, Noninsulin Dependent[Title/Abstract])) OR (Diabetes Mellitus, Maturity-Onset[Title/Abstract])) OR (Diabetes Mellitus, Maturity Onset[Title/Abstract])) OR (Maturity-Onset Diabetes Mellitus[Title/Abstract])) OR (Maturity Onset Diabetes Mellitus[Title/Abstract])) OR (MODY[Title/Abstract])) OR (Diabetes Mellitus, Slow-Onset[Title/Abstract])) OR (Diabetes Mellitus, Slow Onset[Title/Abstract])) OR (Slow-Onset Diabetes Mellitus[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR (Noninsulin-Dependent Diabetes Mellitus[Title/Abstract])) OR (Noninsulin Dependent Diabetes Mellitus[Title/Abstract])) OR (Maturity-Onset Diabetes[Title/Abstract])) OR (Diabetes, Maturity-Onset[Title/Abstract])) OR (Maturity Onset Diabetes[Title/Abstract])) OR (Type 2 Diabetes[Title/Abstract])) OR (Diabetes, Type 2[Title/Abstract])) OR (Diabetes Mellitus, Adult-Onset[Title/Abstract])) OR (Adult-Onset Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus, Adult Onset[Title/Abstract]))
#2	((((((((((((((("Neoplasms"[Mesh]) OR (Tumor[Title/Abstract])) OR (Neoplasm[Title/Abstract])) OR (Tumors[Title/Abstract])) OR (Neoplasia[Title/Abstract])) OR (Neoplasias[Title/Abstract])) OR (Cancer[Title/Abstract])) OR (Cancers[Title/Abstract])) OR (Malignant Neoplasm[Title/Abstract])) OR (Malignancy[Title/Abstract])) OR (Malignancies[Title/Abstract])) OR (Malignant Neoplasms[Title/Abstract])) OR (Neoplasm, Malignant[Title/Abstract])) OR (Neoplasms, Malignant[Title/Abstract])) OR (Benign Neoplasms[Title/Abstract])) OR (Benign Neoplasm[Title/Abstract])) OR (Neoplasms, Benign[Title/Abstract])) OR (Neoplasm, Benign[Title/Abstract]))
#3	(((((("Randomized Controlled Trial" [Publication Type]) OR ("Controlled Clinical Trial" [Publication Type])) OR ("Clinical Trials as Topic"[Mesh])) OR ("Random Allocation"[Mesh])) OR ("Randomized Controlled Trials as Topic"[Mesh])) OR (((((((Randomized Controlled Trial[Title/Abstract]) OR (Controlled Clinical Trial[Title/Abstract])) OR (Clinical Trials as Topic[Title/Abstract])) OR (random allocation[Title/Abstract])) OR (randomized controlled trials as topic[Title/Abstract])) OR (randomly[Title/Abstract])) OR (random[Title/Abstract])) OR (RCT[Title/Abstract]))
#4	#1 AND #2 AND #3

1.2 Web of science

#1	((((((((((((((((((((((((((((((TS=(Diabetes Mellitus, Type 2)) OR TS=(Diabetes Mellitus, Noninsulin-Dependent)) OR TS=(Diabetes Mellitus, Ketosis-Resistant)) OR TS=(Diabetes Mellitus, Ketosis Resistant)) OR TS=(Ketosis-Resistant Diabetes Mellitus)) OR TS=(Diabetes Mellitus, Non Insulin Dependent)) OR TS=(Diabetes Mellitus, Non-Insulin-Dependent)) OR TS=(Non-Insulin-Dependent Diabetes Mellitus)) OR TS=(Diabetes Mellitus, Stable)) OR TS=(Stable Diabetes Mellitus)) OR TS=(Diabetes Mellitus, Type II)) OR TS=(NIDDM)) OR TS=(Diabetes Mellitus, Noninsulin Dependent)) OR TS=(Diabetes Mellitus, Maturity-Onset)) OR TS=(Diabetes Mellitus, Maturity Onset)) OR TS=(Maturity-Onset Diabetes Mellitus)) OR TS=(Maturity Onset Diabetes Mellitus)) OR TS=(MODY)) OR TS=(Diabetes Mellitus, Slow-Onset)) OR TS=(Diabetes Mellitus, Slow Onset)) OR TS=(Slow-Onset Diabetes Mellitus)) OR TS=(Type 2 Diabetes Mellitus)) OR TS=(Noninsulin-Dependent Diabetes Mellitus)) OR TS=(Noninsulin Dependent Diabetes Mellitus)) OR TS=(Maturity-Onset Diabetes)) OR TS=(Diabetes, Maturity-Onset)) OR TS=(Maturity Onset Diabetes)) OR TS=(Type 2 Diabetes)) OR TS=(Diabetes, Type 2)) OR TS=(Diabetes Mellitus, Adult-Onset)) OR TS=(Adult-Onset Diabetes Mellitus)) OR TS=(Diabetes Mellitus, Adult Onset)
#2	((((((((((((((((((((((((((((((TS=(Neoplasms)) OR TS=(Tumor)) OR TS=(Neoplasm)) OR TS=(Tumors)) OR TS=(Neoplasia)) OR TS=(Neoplasias)) OR TS=(Cancer)) OR TS=(Cancers)) OR TS=(Malignant Neoplasm)) OR TS=(Malignancy)) OR TS=(Malignancies)) OR TS=(Malignant Neoplasms)) OR TS=(Neoplasm, Malignant)) OR TS=(Neoplasms, Malignant)) OR TS=(Benign Neoplasms)) OR TS=(Benign Neoplasm)) OR TS=(Neoplasms, Benign)) OR TS=(Neoplasm, Benign)
#3	(((((TS=(Randomized Controlled Trial)) OR TS=(Clinical Trials)) OR TS=(random allocation)) OR TS=(randomly)) OR TS=(random)) OR TS=(RCT)
#4	#1 AND #2 AND #3

1.3 Cochrane

#1	(Diabetes Mellitus, Type 2):ti,ab,kw OR (Diabetes Mellitus, Noninsulin-Dependent):ti,ab,kw OR (Diabetes Mellitus, Ketosis-Resistant):ti,ab,kw OR (Diabetes Mellitus, Ketosis Resistant):ti,ab,kw OR (Ketosis-Resistant Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Non Insulin Dependent):ti,ab,kw OR (Diabetes Mellitus, Non-Insulin-Dependent):ti,ab,kw OR (Non-Insulin-Dependent Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Stable):ti,ab,kw OR (Stable Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Type II):ti,ab,kw OR (NIDDM):ti,ab,kw OR (Diabetes Mellitus, Noninsulin Dependent):ti,ab,kw OR (Diabetes Mellitus, Maturity-Onset):ti,ab,kw OR (Diabetes Mellitus, Maturity Onset):ti,ab,kw OR (Maturity-Onset Diabetes Mellitus):ti,ab,kw OR (Maturity Onset Diabetes Mellitus):ti,ab,kw OR (MODY):ti,ab,kw OR (Diabetes Mellitus, Slow-Onset):ti,ab,kw OR (Diabetes Mellitus, Slow Onset):ti,ab,kw OR (Slow-Onset Diabetes Mellitus):ti,ab,kw OR (Type 2 Diabetes Mellitus):ti,ab,kw OR (Noninsulin-Dependent Diabetes Mellitus):ti,ab,kw OR (Noninsulin Dependent Diabetes Mellitus):ti,ab,kw OR (Maturity-Onset Diabetes):ti,ab,kw OR (Diabetes, Maturity-Onset):ti,ab,kw OR (Maturity Onset Diabetes):ti,ab,kw OR (Type 2 Diabetes):ti,ab,kw OR (Diabetes, Type 2):ti,ab,kw OR (Diabetes
----	--

	Mellitus, Adult-Onset):ti,ab,kw OR (Adult-Onset Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Adult Onset):ti,ab,kw
#2	(Neoplasms):ti,ab,kw OR (Tumor):ti,ab,kw OR (Neoplasm):ti,ab,kw OR (Tumors):ti,ab,kw OR (Neoplasia):ti,ab,kw OR (Neoplasias):ti,ab,kw OR (Cancer):ti,ab,kw OR (Cancers):ti,ab,kw OR (Malignant Neoplasm):ti,ab,kw OR (Malignancy):ti,ab,kw OR (Malignancies):ti,ab,kw OR (Malignant Neoplasms):ti,ab,kw OR (Neoplasm, Malignant):ti,ab,kw OR (Neoplasms, Malignant):ti,ab,kw OR (Benign Neoplasms):ti,ab,kw OR (Benign Neoplasm):ti,ab,kw OR (Neoplasms, Benign):ti,ab,kw OR (Neoplasm, Benign):ti,ab,kw
#3	("randomized clinical trial"):pt OR ("controlled clinical trial"):pt OR ("clinical trial"):ti,ab,kw OR ("random allocation"):ti,ab,kw OR ("clinical trial"):ti,ab,kw ("randomly"):ti,ab,kw
#4	#1 AND # 2 AND #3

1.4 EMBASE

#1	(Diabetes Mellitus, Type 2):ti,ab,kw OR (Diabetes Mellitus, Noninsulin-Dependent):ti,ab,kw OR (Diabetes Mellitus, Ketosis-Resistant):ti,ab,kw OR (Diabetes Mellitus, Ketosis Resistant):ti,ab,kw OR (Ketosis-Resistant Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Non Insulin Dependent):ti,ab,kw OR (Diabetes Mellitus, Non-Insulin-Dependent):ti,ab,kw OR (Non-Insulin-Dependent Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Stable):ti,ab,kw OR (Stable Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Type II):ti,ab,kw OR (NIDDM):ti,ab,kw OR (Diabetes Mellitus, Noninsulin Dependent):ti,ab,kw OR (Diabetes Mellitus, Maturity-Onset):ti,ab,kw OR (Diabetes Mellitus, Maturity Onset):ti,ab,kw OR (Maturity-Onset Diabetes Mellitus):ti,ab,kw OR (Maturity Onset Diabetes Mellitus):ti,ab,kw OR (MODY):ti,ab,kw OR (Diabetes Mellitus, Slow-Onset):ti,ab,kw OR (Diabetes Mellitus, Slow Onset):ti,ab,kw OR (Slow-Onset Diabetes Mellitus):ti,ab,kw OR (Type 2 Diabetes Mellitus):ti,ab,kw OR (Noninsulin-Dependent Diabetes Mellitus):ti,ab,kw OR (Noninsulin Dependent Diabetes Mellitus):ti,ab,kw OR (Maturity-Onset Diabetes):ti,ab,kw OR (Diabetes, Maturity-Onset):ti,ab,kw OR (Maturity Onset Diabetes):ti,ab,kw OR (Type 2 Diabetes):ti,ab,kw OR (Diabetes, Type 2):ti,ab,kw OR (Diabetes Mellitus, Adult-Onset):ti,ab,kw OR (Adult-Onset Diabetes Mellitus):ti,ab,kw OR (Diabetes Mellitus, Adult Onset):ti,ab,kw
#2	'Neoplasms':ti,ab,kw OR 'Tumor':ti,ab,kw OR 'Neoplasm':ti,ab,kw OR 'Neoplasm':ti,ab,kw OR 'Tumors':ti,ab,kw OR 'Cancer':ti,ab,kw OR 'Cancers':ti,ab,kw OR 'Malignancy':ti,ab,kw OR 'Malignancies':ti,ab,kw OR 'Malignant Neoplasms':ti,ab,kw OR 'Neoplasm, Malignant':ti,ab,kw OR 'Neoplasms, Malignant':ti,ab,kw OR 'Benign Neoplasms':ti,ab,kw OR 'Benign Neoplasm':ti,ab,kw OR 'Neoplasms, Benign':ti,ab,kw OR 'Neoplasm, Benign':ti,ab,kw
#3	("randomized clinical trial"):pt OR ("controlled clinical trial"):pt OR ("clinical trial"):ti,ab,kw OR ("random allocation"):ti,ab,kw OR ("clinical trial"):ti,ab,kw ("randomly"):ti,ab,kw
#4	#1 AND #2 AND #3

2. Basic Characteristics of Included Literature

Table 2-1 Basic Characteristics of Included Literature

Study	Clinical trial registration number	Design	Intervention duration	Patients (n)	Intervention measures	Age (year)	Sex (male/female)	BMI (kg/m ²) (Inclusion Criteria)	BMI (kg/m ²)	HbA1c (%) (Inclusion Criteria)	HbA1c (%)	Cancer was designated as a predefined outcome
Baptist 2012(1)	NCT00622284	parallel-group, non-inferiority double-blind trial	104w	1552	linagliptin glimepiride	59.8(9.4)	933/618	≤40	30.2(4.7)	6.0-10	7.7(0.9)	No
Masaru 2021(2)	jRCTs031180205	52-week randomized open-label trial	52w	111	Ipragliflozin Sitagliptin	59.2(10.8)	68/53	-	26.6(3.8)	6.5-10	7.5(0.72)	No
Mathieu 2014(3)	NCT01388361	multinational, Phase 3b, open-label, randomized, treat-to-target study	104w	177	liraglutide insulin	61(9)	-	-	32.3(5.2)	-	7.7(0.7)	No
Nauck 2007(4)	NCT00082407	52-week, open-label, non-inferiority trial	52w	501	Exenatide Premixed insulin	59(9)	403/98	25-40	30.4(4.1)	7.0-11	8.6(1.1)	No
Philip 2017(5)	NCT01717313	multicenter, double-blind, randomized, parallel-group trial	54w	329	Omarigliptin Placebo	57.2(9.5)	192/137	-	31(6.4)	6.5-10	8.1(1)	No
Yehuda 2017(6)	NCT01682759	randomized, double-blind, non-inferiority trial	54w	751	omarigliptin glimepiride	58(10)	414/437	-	31.5(5.6)	6.5-9	7.5(0.8)	No
Gantz 2017(7)	NCT01703208	randomized, placebo-controlled study	96w	4202	Omarigliptin Placebo	63.7(8.5)	2948/1254	-	31.3(5.6)	6.5-10	8(0.9)	No
Adrian 2018(8)	NCT02465515	double-blind, randomised placebo-controlled trial	1.5y	9463	Albiglutide Placebo	64.2(8.7)	6569/2894	-	32.3(5.9)	>7	8.7(1.5)	Yes
William 2013(9)	NCT00968708	multicenter, randomized, double-blind trial	18m	5380	Alogliptin Placebo	61		-	28.7	6.5-11	8.0(1.1)	Yes
Perkovic 2019(10)	NCT02065791	double-blind, randomized trial	2.62y	4401	Canagliflozin Placebo	63(9.0)	2907/1494	-	31.3(6.2)	6.5-12	8.3(1.3)	No
Vlado 2018(11)	NCT01032629; NCT01989754	randomised clinical trial	78w	10142	Canagliflozin Placebo	-	-	-	-	-	-	No

GUNTRAM 2013(12)	NCT01137812	randomized, double-blind, active-controlled, phase 3 study	52w	755	canagliflozin sitagliptin	56.7(9.5)	422/333	-	31.6(6.9)	7-10.5	8.1(0.9)	No
Lawrence 2015(13)	NCT00968812	randomized, double-blind study	104w	1450	Canagliflozin Glimepiride	56.2(9.2)	756/694	-	31.0(5.4)	7-9.5	7.8(0.8)	No
Martin 2014(14)	NCT01167881	randomised, active-controlled, double-blind, phase 3 trial	104w	1549	empagliflozin glimepiride	56(10.4)	853/696	≤45	30.1(5.3)	7.0-10	7.92(0.84)	No
Steven 2008(15)	NCT00225277	Double-blind, randomized, multicenter trial	18m	543	Pioglitazone Glimepiride	59.8(9.3)	366/177	-	32.1(5.3)	6.0-10	7.4(1.0)	No
Lawrence 2014(16)	NCT01042977	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study	52w	962	Dapagliflozin Placebo	63.8(7.3)	644/318	-	32.8(5.5)	7.0-10	8.1(0.8)	No
Clifford 2013(17)	NCT00528879	randomized, double-blind, placebo-controlled 102-week trial	102w	546	Dapagliflozin Placebo	54(9.5)	292/254	-	31.5(5.0)	>8	8(0.9)	No
Wiviott 2019(18)	NCT01730534	randomized, double-blind, multinational, placebo-controlled, phase 3 trial	4.2y	17160	Dapagliflozin Placebo	64(6.8)	10738/6422	-	32.1(6.1)	6.5-12	8.3(1.2)	No
Wilding 2014(19)	NCT00673231	randomized, placebo-controlled, double-blinded, multicentre trial	56w	800	Dapagliflozin Placebo	59(8)	382/418	-	33.1(5)	7.5-10.5	8.5(0.8)	No
Bolinder 2014(20)	NCT00855166	randomized, double-blind, placebo-controlled study	102w	182	Dapagliflozin Placebo	60.7(7.49)	100/80	≥25	31.87(3.9)	6.5-8.5	7.17(0.49)	No
MICHAEL 2011(21)	NCT00660907	double-blind, multicenter, active-controlled, noninferiority trial	52w	801	dapagliflozin glipizide	58.4(9.58)	441/360	-	31.47(5.0 1)	6.5-10	7.72(0.87)	No
William 2015(22)	NCT01031680	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study	52w	922	dapagliflozin Placebo	63(7.3)	632/290	-	32.8(6)	-	8.18(0.84)	No
Yuichiro 2020(23)	NCT03018028	phase 2/3a, randomised, controlled trial	52w	243	oral semaglutide liraglutide placebo	59(10)	191/52	-	26.5(4)	6.5-10	8.2(1)	No
Hertzel 2019(24)	NCT01394952	a double-blind, randomised placebo-controlled trial	5.4y	9901	dulaglutide placebo	66.2(6.5)	5312/4589	≥23	32.3(5.8)	≥9.5	7.4(1.1)	Yes
Katherine 2018(25)	NCT01621178	multicentre, open-label, randomised trial	52w	576	dulaglutide insulin glargine	64.5(8.6)	301/275	-	32.5(5.2)	7.5-10.5	8.6(1)	Yes
Matthaei 2015(26)	-	international, multicentre, randomized, double-blind,	52w	219	dapagliflozin placebo	61(9.5)	106/110	-	32(4.7)	7-10.5	8.2(0.9)	No

		parallel-group, placebo-controlled phase IIIb study										
DelPrato 2014(27)	NCT00856284	multicentre, double-blind, active-controlled study	104w	2639	alogliptin glipizide	55.4(0.7)	1312/1327	-	31.2(5.3)	7.0-10	7.6(0.6)	No
Julio 2019(28)	NCT02607865	Randomized, double-blind, double-dummy, parallel-group, phase 3a trial	78w	1864	Oral Semaglutide Sitagliptin	58(10)	984/879	-	32.6(6.4)	7.0-10.5	8.3(1.0)	Yes
Julio 2019(29)	NCT01243424	Randomized, double-blind, active-controlled, noninferiority trial	6.3y	6042	Linagliptin Glimepiride	64(9.5)	-	-	30.1(5.2)	6.5-8.5	7.2(0.6)	Yes
Julio 2018(30)	NCT01897532	Randomized, placebo-controlled, multicenter noninferiority trial	2.2y	6991	Linagliptin Placebo	65.8(9.1)	4390/2589	-	31.4(5.4)	6.5-10	8.0(1)	Yes
Monika 2022(31)	NCT03689374	randomized, open-label, multinational, phase 3b trial	52w	1748	semaglutide insulin	61.2(9.4)	894/854	-	31.5(5.5)	7.5-10	8.6(0.7)	No
Hertzel 2009(32)	NCT00116831	randomized, double-blind, controlled 18-month study	18m	672	Glipizide Rosiglitazone	61(8.7)	456/216	-	29.5(5.4)	6.5-10	7.2(0.9)	No
Jennifer 2015(33)	NCT00790205	randomized, double-blind study	3.0y	14671	sitagliptin placebo	65.5 (8.0)	10374/4297	-	30.2(5.6)	6.5-8.0	7.2(0.5)	Yes
HANNELE 2013(34)	NCT00954447	randomized, double-blind study	52w	1261	linagliptin placebo	60 (10)	658/603	≤45	31(5)	7.0-10	8.3(0.85)	No
James 2017(35)	NCT01106651	randomized, double-blind, placebo-controlled study	104w	666	canagliflozin placebo	-	381/385	-	31.6(4.7)	7.0-10	7.8(0.8)	No
Rury 2022 (36)	NCT01144338	pragmatic, randomized, double-blind, placebo-controlled, event-driven trial	3.2y	14752	exenatide placebo	61.9(9.4)	9149/5603	-	31.8(3.5)	6.5-10	8.0(0.8)	Yes
Olga 2017(37)	NCT00700856	multicentre, randomised, pragmatic clinical trial	57.3m	3028	pioglitazone sulfonylureas	62.3(6.5)	1774/1254	20-45	30.3(4.5)	7-9.0	7.68(0.5)	Yes
Yutaka 2012(38)	NCT01318135	randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study	64w	592	glimepiride Metformin	-	394/195	-	-	-	-	No
Lavalle 2013(39)	NCT01106677	randomised, double-blind, four-arm, parallel-group, Phase 3 study	52w	1284	canagliflozin sitagliptin	55.4(9.4)	605/679	-	31.8(6.2)	7-10.5	7.9(0.9)	No
Wilding 2013(40)	NCT01106625	randomised, double-blind, placebo-controlled, Phase 3 study	52w	469	canagliflozin placebo	56.8(9.3)	239/280	-	331.(6.5)	7-10.5	8.1(0.9)	No

Dirk 2018(41)	NCT02471404	52-week, multicentre, double-blind, active-controlled study	52w	939	saxagliptin glimepiride	58.4(8.6)	600/339	≤45	32.9(5.1)	7.5-10.5	8.3(0.7)	No
Anthony 2014(42)	NCT01164501	phase 3, randomised, double-blind, parallel-group, placebo-controlled trial	52w	290	empagliflozin placebo	62.6(8.3)	177/113	≤45	31.5(5.6)	7.0-10	8.03(0.79)	No
Hirohito 2019(43)	NCT02589639	multicentre, double-blind, parallel-group study	52w	266	Empagliflozin placebo	58.7(10)	193/73	22-40	26.9(3.2)	7.5-10	8.8(0.7)	No
Henry 2014(44)	NCT00722371	randomized, double-blinded, placebo-controlled trial	54w	1615	sitagliptin pioglitazone	-	912/703	-	-	7.5-11	-	No
Wang 2018(45)	NCT01648582	open-label, randomized phase III trial	52w	774	dulaglutide insulin glargine	55.0(9.6)	417/338	19-35	26.8(3.7)	7.0-11	8.4(1.1)	No
Francesco 2015(46)	NCT01075282	open-label comparator (double-blind to dulaglutide dose), parallel-arm, randomized, multicenter trial	78w	807	Dulaglutide Glargine	57(10)	414/393	23-45	32(5)	7.0-11	8.1(1)	No
Michael 2016(47)	NCT00849017	randomised, placebo-controlled trial	52w	309	Albiglutide Placebo	52.6(11.5)	168/135	20-45	33.5(5.3)	7.0-10	8.1(0.9)	Yes
Reusch 2014(48)	NCT00849056	randomized, double-blind, placebo-controlled trial	52w	301	albiglutide placebo	55(9.67)	180/121	20-45	34.1(5.8)	7.0-10	8.1(0.9)	No
Ildiko 2019(49)	NCT03136484	double-blind, phase 3b, randomized controlled trial	52w	788	semaglutide canagliflozin	56.6(10.9)	424/364	-	32.3(6.8)	7.0-10.5	8.3(1.0)	No
Ahrén 2017(50)	NCT01930188	double-blind, phase 3a, randomised trial	56w	1231	semaglutide sitagliptin	55(10)	620/605	-	32.5(6)	7.0-10.5	8.1(0.9)	No
Thomas 2019(51)	NCT02849080	multicentre, open-label, randomised, phase 3a trial	52w	504	semaglutide sitagliptin	57.4(10)	285/219	-	31.5(6.3)	7.5-9.5	8.3(0.6)	No
Adrian 2012(52)	NCT00350779	randomized placebo-controlled 54-week trial	54w	278	Sitagliptin Placebo	54.6(9.7)	151/111	-	30.5(5.9)	-	8.8(1)	No
Williams 2010(53)	NCT00103857	randomized, double-blind, factorial study	54w	1091	sitagliptin metformin placebo	-	606/602	-	-	7.5-11	9.0(1.2)	No
JUAN 2013(54)	NCT00509262	multinational, randomized, double-blind, parallel-group, 54-week study	54w	426	Sitagliptin Glipizide	64.2(10.1)	253/170	-	-	7.0-9	-	No
Samuel 2017(55)	NCT02036515	placebo-controlled randomized study	52w	464	Ertugliflozin Placebo	59.1(9)	263/199	-	30.8(6)	7.0-10.5	8(0.9)	No

Nauck 2006(56)	NCT00094770	randomized, double-blind, non-inferiority trial	52w	1172	sitagliptin glipizide	56.7(9.5)	694/478	-	31.3(5.1)	-	7.7(0.9)	No
Lawrence 2014(57)	NCT01098539	randomized, double-blind, multicenter, 52-week study	52w	495	Albiglutide Sitagliptin	63.3(8.69)	266/229	-	30.39(5.6)	-	8.18(1)	No
Home 2014(58)	NCT00839527	randomized, double-blind, parallel-group, multicentrestudy	52w	685	Pioglitazone Albiglutide Placebo	55.2(9.5)	353/310	20-45	32.2(5.5)	7.0-10	8.24(0.91)	No
Scherthaner 2015(59)	NCT01006603	multinational, randomized, double-blind, phaseIIIb/Iv study	52w	720	saxagliptin glimepiride	72.6(5.6)	445/275	-	29.6(4.9)	7.0-9	7.6(0.66)	No
Davies 2015(60)	NCT01272232	randomized,double- blind,placebo-controlled, parallel-grouptrial	56w	846	Liraglutide placebo	55(10.5)	425/421	≥27	37.2(6.9)	7.0-10	8.0(0.8)	No
Bernard 2019(61)	NCT03021187	52-week, double-blind trial	52w	731	Semaglutide Placebo	61(10)	395/336	-	31(6.7)	<7	8.2(0.7)	No
Christopher 2015(62)	NCT01210001	randomized, placebo- controlled, Phase III trial	52w	498	Empagliflozin Placebo	54.5(9.8)	241/257	≤45	29.2(5.5)	7.0-10	8.09(0.88)	No
Ryuzo 2018(63)	NCT02453555	randomized, placebo- controlled trial	52w	433	empagliflozin placebo	60(10)	214/61	≤40	26.3(4)	-	8.3(0.7)	No
Bernard 2016(64)	NCT01131676	randomized, double-blind, placebo-controlled trial	3.1y	7020	Empagliflozin placebo	63(8.8)	5016/2004	≤45	30.7(5.3)	7.0-10	8.1(0.9)	No
Priscilla 2018(65)	NCT01999218	phase III, double-blind, non- inferiority study	52w	1325	Ertugliflozin Glimepiride	58.2(9.6)	642/683	-	31.4(6.1)	7.0-9	7.8(0.6)	No
Home 2010(66)	NCT00279045; NCT00379769	randomised controlled trial	4y	4351	Metformin Rosiglitazone Glibenclamide	-	-	-	-	-	-	Yes
Benjamin 2016(67)	NCT01107886	multicenter, randomized, double-blind, placebo- controlled, phase 4 trial	2.1y	16492	Saxagliptin Placebo	65.1(8.6)	11037/5455	-	31.2(5.6)	6.5-12	8(1.4)	No
Ahren 2014(68)	NCT00838903	Randomized, Double-Blind, Placebo and Active- Controlled Trial	104w	1012	Sitagliptin Glimepiride Albiglutide	54.5(9.9.7)	482/530	-	-	-	-	Yes
Peter 2014(69)	NCT00838916	randomised, open-label, parallel-group multicentre clinical trial	52w	779	Albiglutide insulin glargine	55.5(9.5)	418/327	20-45	33.1(5.5)	7.0-10	8.31(0.92)	No
Rosenstock 2015(70)	NCT01011868	randomized, double-blind, placebo-controlled trial	78w	494	Empagliflozin Placebo	58.8(9.9)	-	≤45	-	7.0-10	8.2(0.8)	No

Julio 2014(71)	NCT01306214	randomized, double-blind, placebo-controlled, parallel-group study	52w	563	Empagliflozin Placebo	56.7(9.5)	-	30-45	34.8(4.1)	7.5-10	8.3(0.7)	No
Andrew 2015(72)	NCT01422876	phase III, randomized, double-blind, parallel-group study	52w	677	Empagliflozin Linagliptin	55(10)	359/318	≤45	31.5(5.7)	7-10.5	8(1)	No
Alan 2009(73)	NCT00294723	randomised, 52-week, phase III, double-blind, parallel-treatment trial	52w	746	Liraglutide glimepiride	53(11)	371/375	≤45	33(5.8)	7.0-11	8.3(1.1)	Yes
Marc 2015(74)	NCT01147250	multicenter, randomized, double-blind, placebo-controlled trial	25m	6068	Lixisenatide placebo	60.3(9.7)	4207/1861	-	30.2(5.7)	5.5-11	7.7(1.3)	Yes
Bode 2015(75)	NCT01106651	randomized,double-blind,phaseIIIstudy	104w	714	canagliflozin Placebo	63.6(6.2)	396/318	-	31.6(4.6)	7.0-10	7.7(0.8)	No
Donald 2014(76)	NCT00663260	randomized, double-blind, placebo-controlled study	104w	252	Dapagliflozin Placebo	67(8.5)	164/88	≤45	-	7.0-11	8.3(1)	No
Michael 2017(77)	NCT01179048	international, phase 3b, randomized, double-blind, controlled trial	3.8y	9340	Liraglutide Placebo	64.3(7.2)	6003/3337	-	-	-	-	Yes
Lawrence 2015(78)	NCT01191268	randomised, open-label, phase 3, non-inferiority study	52w	884	Dulaglutide Glargine	59(9.2)	473/311	23-45	32.5(5.2)	7.0-11	8.5(1)	No
Pratley 2011 (79)	NCT00700817	randomised, parallel-group, open-label trial	52w	665	Liraglutide Liraglutide	55.3(9.2)	352/313	-	32.8(5.2)	7.5-10	8.5(0.8)	No
Mansoor 2019(80)	NCT02692716	event-driven, randomized, double-blind, placebo-controlled trial	15.9m	3183	Oral Semaglutide placebo	66(7)	2176/1007	-	32.3(6.5)	-	8.2(1.6)	No
Richard 2019(81)	NCT02863419	randomised, double-blind, double-dummy, phase 3a trial	52w	711	Oral semaglutide Liraglutide Placebo	56(10)	370/341	-	33(6.3)	7-9.5	8(0.7)	No
Michael 2015(82)	NCT01289990	Phase III randomized controlled trial	76w	899	Empagliflozin Sitagliptin Placebo	55(11)	551/348	≤45	28.4(5.6)	7.0-10	7.88(0.82)	No
Burkhard 2013 (83)	NCT00575588	randomised controlled trial	104w	858	Saxagliptin glipizide	57.5(30)	444/414	-	31.4(16)	6.5-10	7.7(2)	No
John 2005(84)	NCT00174993	randomised controlled trial	34.5m	5238	Pioglitazone Placebo	61.8(7.7)	3463/1775	-	31(4.8)	≥6.5	7.8(0.8)	No
Steven 2016(85)	NCT01720446	randomized, double-blind, placebo-controlled, parallel-group trial	104w	3297	Semaglutide Placebo	64.6(7.4)	2002/1295	-	-	≥7	8.7(1.5)	Yes

Christian 2021(86)	NCT01455896	non-inferiority randomized controlled trial	16m	4156	exenatide placebo	63(5)	2631/1525	-	32(0.6)	≥ 6.5	8(0.8)	Yes
Wadden 2013(87)	NCT00781937	randomized controlled study	56w	422	liraglutide placebo	46.2(11.5)	79/343	≥ 27	37.9(6.2)	-	-	No

w: week; m: month; y: year.

3. Assessment of Included Literature Quality




Figure 3-1 Overall Quality Assessment of Included Studies

[illegible]

Figure 3-2 Quality Assessment of Included Studies

4. Risk of bias




Figure 4-1 CINeMA Results of any cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:DPP-4i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	1	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Biguanide:Sulfonylureas	1	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
DPP-4i:GLP-1RA	1	No concerns	Low risk	No concerns	No concerns	No concerns	No concerns	High
DPP-4i:Placebo	5	No concerns	Low risk	No concerns	No concerns	No concerns	No concerns	High
DPP-4i:Sulfonylureas	2	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:Placebo	6	No concerns	Low risk	No concerns	No concerns	No concerns	Some concerns	Moderate
GLP-1RA:SGLT-2i	1	No concerns	Low risk	No concerns	No concerns	Major concerns	No concerns	Low
Placebo:SGLT-2i	4	No concerns	Low risk	No concerns	No concerns	No concerns	No concerns	High
Placebo:Thiazolidinediones	1	No concerns	Low risk	No concerns	No concerns	Some concerns	No concerns	Moderate
Sulfonylureas:Thiazolidinediones	2	No concerns	Low risk	No concerns	No concerns	No concerns	No concerns	High
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:Sulfonylureas	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:Thiazolidinediones	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Placebo:Sulfonylureas	0	No concerns	Low risk	No concerns	No concerns	No concerns	No concerns	High
SGLT-2i:Sulfonylureas	0	No concerns	Low risk	No concerns	No concerns	Major concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-2 Risk of bias in any cancer




Figure 4-3 CINeMA Results of lung cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:DPP-4i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Sulfonyleureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonyleureas	5	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	8	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	9	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Placebo:Thiazolidinediones	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonyleureas:Thiazolidinediones	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Insulin:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low

Figure 4-4 Risk of bias in lung cancer




Figure 4-5 CINeMA Results of bronchial cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
DPP-4i:Placebo	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonyleureas	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Placebo	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-6 Risk of bias in bronchial cancer




Figure 4-7 CINeMA Results of thyroid cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
DPP-4i:GLP-1RA	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonyleureas	5	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	13	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonyleureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonyleureas:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-8 Risk of bias in thyroid cancer




Figure 4-9 CINeMA Results of gastric cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:Sulfonylureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonylureas	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonylureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonylureas:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:DPP-4i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-10 Risk of bias in gastric cancer




Figure 4-11 CINeMA Results of pancreatic cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:DPP-4i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Sulfonyleureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Very low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	5	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonyleureas	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	9	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonyleureas:Thiazolidinediones	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	High
GLP-1RA:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-12 Risk of bias in pancreatic cancer




Figure 4-13 CINeMA Results of rectal cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
DPP-4i:GLP-1RA	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonylureas	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	10	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonylureas:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-14 Risk of bias in rectal cancer




Figure 4-15 CINeMA Results of colon cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
DPP-4i:GLP-1RA	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	7	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
DPP-4i:SGLT-2i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonyleureas	6	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:Placebo	10	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonyleureas	1	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Placebo:SGLT-2i	10	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonyleureas	3	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonyleureas	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate

Figure 4-16 Risk of bias in colon cancer




Figure 4-17 CINeMA Results of bladder cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:DPP-4i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonylureas	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	4	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	10	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonylureas	1	No concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	1	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Placebo:SGLT-2i	8	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Placebo:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonylureas	1	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Sulfonylureas:Thiazolidinediones	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate

Figure 4-18 Risk of bias in bladder cancer




Figure 4-19 CINEMA Results of prostate cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:DPP-4i	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Sulfonylureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	4	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
DPP-4i:Placebo	9	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonylureas	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	5	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	12	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:SGLT-2i	1	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
GLP-1RA:Sulfonylureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	13	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate
Placebo:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonylureas	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonylureas:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-20 Risk of bias in prostate cancer




Figure 4-21 CINeMA Results of uterine cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonyleureas	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	8	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	5	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonyleureas	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonyleureas:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:DPP-4i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-22 Risk of bias in uterine cancer

Figure 4-24 Risk of bias in breast cancer




Figure 4-25 CINeMA Results of Hepatocellular cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Placebo	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	5	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonylureas:Thiazolidinediones	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-26 Risk of bias in Hepatocellular cancer




Figure 4-27 CINeMA Results of renal cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:Sulfonylureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	4	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonylureas	5	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	9	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonylureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonylureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonylureas:Thiazolidinediones	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:DPP-4i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonylureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low

Figure 4-28 Risk of bias in renal cancer



Figure 4-29 CINeMA Results of hematologic cancer

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Biguanide:Sulfonyleureas	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:GLP-1RA	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Sulfonyleureas	3	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Insulin	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
GLP-1RA:Placebo	7	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:SGLT-2i	6	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Sulfonyleureas	2	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Sulfonyleureas:Thiazolidinediones	1	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:DPP-4i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:GLP-1RA	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Biguanide:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Insulin	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:Placebo	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
DPP-4i:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
GLP-1RA:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Placebo	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low
Insulin:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Insulin:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:SGLT-2i	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Sulfonyleureas	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Placebo:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
SGLT-2i:Thiazolidinediones	0	No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low


Figure 4-30 Risk of bias in hematologic cancer

Table 4-1 Inconsistency analysis of different results

Outcomes	Study	Patients	Events	chi2	P-value
Any cancer	22	126,343	6731	3.98	0.6800
Lung cancer	37	166,431	297	4.78	0.9052
Bronchial cancer	19	140,492	43	0.65	0.7222
Thyroid cancer	34	149,757	85	3.97	0.5399
Gastric cancer	30	161,997	103	2.06	0.7245
Pancreatic cancer	31	165,210	176	7.60	0.2691
Rectal cancer	25	152,793	74	3.82	0.7017
Colon cancer	39	170,345	243	1.74	0.8839
Bladder cancer	40	175,500	261	6.26	0.9022
Prostate cancer	55	183,497	760	7.59	0.9094
Uterine cancer	32	137,166	80	1.72	0.9884
Breast cancer	57	191,966	254	7.46	0.9437
Hepatocellular cancer	20	154,776	90	2.17	0.5384
Renal cancer	35	169,333	111	2.34	0.9848
Hematologic cancer	24	150,318	80	0.18	0.9118

5. Results


5.1 Any Cancer



5.1-1 Rank Probability of any cancer


DPP-4i						
0.06 (-0.28,0.40)	Biguanide					
-0.08 (-0.34,0.08)	-0.14 (-0.51,0.22)	SGLT-2i				
-0.08 (-0.25,0.07)	-0.14 (-0.46,0.18)	0.00 (-0.21,0.21)	Sulfonylureas			
-0.09 (-0.29,0.12)	-0.15 (-0.47,0.18)	-0.06 (-0.24,0.12)	-0.01 (-0.20,0.18)	Thiazolidinediones		
-0.10 (-0.39,-0.08)	-0.16 (-0.58,0.18)	-0.02 (-0.15,0.11)	-0.02 (-0.18,0.15)	-0.01 (-0.21,0.19)	Placebo	
-0.14 (-0.27,-0.02)	-0.20 (-0.55,0.15)	-0.06 (-0.21,0.09)	-0.06 (-0.25,0.12)	-0.06 (-0.27,0.16)	-0.05 (-0.12,0.02)	GLP-1RA

5.1-2 League Table of any cancer




5.1-3 Funnel plot of any cancer

5.2 Lung Cancer



5.2-1 Rank Probability of lung cancer


5.3 Bronchial Cancer



5.3-1 Rank Probability of bronchial cancer


Rank 1				
GLP1RA	Placebo			
GLP1RA	GLP1RA	GLP1RA		
GLP1RA	GLP1RA	GLP1RA	GLP1RA	
GLP1RA	GLP1RA	GLP1RA	GLP1RA	Sulfonylureas

5.3-2 League Table of bronchial cancer



5.3-3 Funnel plot of bronchial cancer


5.4 Thyroid Cancer



5.4-1 Rank Probability of thyroid cancer


Effect size		Thyroid cancer		Breast		Prostate		ESD 0.25		No publication		OLP 0.84	
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25
ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25	ESD 0.25

5.4-2 League Table of thyroid cancer



5.4-3 Funnel plot of thyroid cancer


5.5 Gastric Cancer



5.5-1 Rank Probability of gastric cancer


Epoxide	Fluoride/cation	Allylphenyl	OH/ES	Isocyan	OTFA	Fluoride	OTFA
-0.70 (-0.84, 0.44)	-0.54 (-1.07, 0.00)	-0.19 (-1.41, 1.04)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)
-0.72 (-0.76, 0.33)	-0.54 (-1.07, 0.00)	-0.19 (-1.41, 1.04)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)
-0.88 (-0.84, 0.80)	-0.54 (-1.07, 0.00)	-0.19 (-1.41, 1.04)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)
-0.85 (-0.84, 0.33)	-0.54 (-1.07, 0.00)	-0.19 (-1.41, 1.04)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)
-0.89 (-0.79, 0.70)	-0.54 (-1.07, 0.00)	-0.19 (-1.41, 1.04)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)
-1.03 (-0.93, 0.33)	-0.54 (-1.07, 0.00)	-0.19 (-1.41, 1.04)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)
-1.34 (-0.84, 0.33)	-0.54 (-1.07, 0.00)	-0.19 (-1.41, 1.04)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)	-0.01 (-0.33, 0.31)

5.5-2 League Table of gastric cancer




5.5-3 Funnel plot of gastric cancer

5.6 Pancreatic Cancer



5.6-1 Rank Probability of pancreatic cancer


5.7 Rectal Cancer



5.7-1 Rank Probability of rectal cancer


DPP4i		Thiazolidinediones		Placebo		SGLT2i		Sulfonylureas		GLP-1RA		Insulin	
0.02 (-0.17, 0.21)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)
-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)	-0.07 (-0.26, 0.12)

5.7-2 League Table of rectal cancer



5.7-3 Funnel plot of rectal cancer


5.8 Colon Cancer



5.8-1 Rank Probability of colon cancer


Meta-analysis				
-0.28 [-0.27, 0.17]	DFT-4			
-0.78 [-0.39, 0.91]	-0.25 [-0.63, 0.20]	Flaxseed		
-0.80 [-0.39, 0.99]	-0.20 [-0.27, 0.77]	-0.02 [-0.39, 0.99]	WOL-2	
0.80 [-0.79, 0.99]	-0.20 [-0.27, 0.39]	0.00 [-0.40, 0.40]	-0.00 [-0.40, 0.40]	Overall

5.8-2 League Table of colon cancer



5.8-3 Funnel plot of colon cancer


5.9 Bladder Cancer



5.9-1 Rank Probability of bladder cancer


Rank									
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

5.9-2 League Table of bladder cancer



5.9-3 Funnel plot of bladder cancer


5.10 Prostate Cancer



5.10-1 Rank Probability of prostate cancer


GEP (BA)		Results		Significance		Therapeutic outcome		Surgical outcome		Prostate		DPP-4		MCT-5	
0.22 (-1.27, 1.69)		-0.22 (-2.04, 1.40)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	
-0.20 (-1.24, 0.79)		-0.42 (-2.14, 1.32)		-0.09 (-0.40, 0.22)		-0.00 (-0.04, 0.04)		-0.01 (-0.01, 0.01)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)		-0.00 (-0.00, 0.00)	

5.10-2 League Table of prostate cancer



5.10-3 Funnel plot of prostate cancer


5.11 Uterine Cancer



5.11-1 Rank Probability of uterine cancer


[illegible]

5.11-2 League Table of uterine cancer



5.11-3 Funnel plot of uterine cancer


5.12 Breast Cancer



5.12-1 Rank Probability of breast cancer


Pharmaceuticals		NoPharmaceutical		Biphenols		DHP-6		GAP-38a		Plestin		SOLT-3		Insulin	
-0.08 (-0.86,0.48)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.11 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.18 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.11 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.14 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.14 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.14 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.14 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.14 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	
-0.14 (-1.29,0.49)		-0.29 (-1.23,0.59)		-0.09 (-1.11,1.01)		-0.17 (-0.89,0.55)		-0.01 (-0.49,0.50)		-0.14 (-0.86,0.59)		-0.04 (-0.49,0.42)		-0.04 (-0.49,0.42)	

5.12-2 League Table of breast cancer



5.12-3 Funnel plot of breast cancer


5.13 Hepatocellular Cancer



5.13-1 Rank Probability of hepatocellular cancer


Biguanide						
-1.58 (-4.68,1.47)	Sulfonylureas					
-1.74 (-4.68,1.21)	-0.14 (-1.58,1.21)	Thiazolidinediones				
-1.62 (-3.67,1.23)	-0.33 (-2.04,1.38)	-0.19 (-1.34,0.99)	GLP1RA			
-2.02 (-3.18,1.07)	-0.42 (-2.02,1.17)	-0.28 (-1.28,0.72)	-0.89 (-0.79,0.90)	Placebo		
-2.16 (-3.31,1.08)	-0.57 (-2.15,1.16)	-0.43 (-1.63,0.78)	-0.34 (-1.43,0.85)	-0.14 (-1.13,0.84)	SGLT2i	

5.13-2 League Table of hepatocellular cancer



5.13-3 Funnel plot of hepatocellular cancer


5.14 Renal Cancer



5.14-1 Rank Probability of renal cancer


GLP1RA	Bigaide	Insulin	Placebo	DPP4i	SGLT2i	Thiazolidinediones	Sulfonylureas
0.19 (-1.85,2.33)	0.28 (-1.66,4.02)	-0.48 (-3.75,2.79)	-0.33 (-1.03,0.38)	-0.07 (-1.07,0.92)			
0.39 (-2.81,3.58)	-0.28 (-2.37,1.80)	-0.81 (-4.13,2.51)	-0.33 (-1.03,0.38)	-0.28 (-1.68,1.12)	-0.13 (-1.73,1.49)		
-0.89 (-4.73,0.55)	-0.61 (-2.85,1.40)	-0.88 (-4.23,2.47)	-0.40 (-1.16,0.36)	-0.28 (-1.68,1.12)			
-0.42 (-1.28,0.45)	-0.68 (-2.85,1.48)	-1.01 (-4.57,2.55)	-0.53 (-2.02,0.96)	-0.28 (-1.68,1.12)			
-0.49 (-1.47,0.50)	-0.81 (-2.81,1.19)	-1.01 (-4.57,2.55)	-0.53 (-2.02,0.96)	-0.28 (-1.68,1.12)			
-0.82 (-2.17,0.53)	-0.81 (-2.87,1.05)	-1.01 (-4.61,2.59)	-0.53 (-2.02,0.96)	-0.28 (-1.68,1.12)			
-0.62 (-1.76,0.52)						0.89 (-1.29,1.28)	

5.14-2 League Table of renal cancer



5.14-3 Funnel plot of renal cancer


5.15 Hematologic Cancer



5.15-1 Rank Probability of hematologic cancer

Biguanide		Insulin		Sulfonylureas		Thiazolidinediones		DPP4i		SGLT2i		Placebo		GLP1RA	
0.13 (-0.46,0.73)		-0.42 (-0.75,0.00)		-0.02 (-1.29,1.26)		-0.16 (-1.68,1.37)		-0.19 (-0.47,1.09)		-0.02 (-1.37,1.32)		-0.06 (-0.96,0.83)			
-0.28 (-1.76,1.19)		-0.44 (-0.94,0.07)		-0.18 (-1.19,0.82)		-0.56 (-2.12,1.01)		-0.22 (-0.35,1.19)		-0.08 (-1.09,0.92)					
-0.50 (-1.79,1.17)		-0.69 (-0.79,0.59)		-0.38 (-1.81,1.05)		-0.58 (-2.53,1.37)									
-0.47 (-2.21,1.27)		-0.79 (-0.99,0.41)		-0.48 (-1.98,1.16)		-0.44 (-2.18,1.30)									
-0.66 (-2.68,1.37)		-0.82 (-0.98,0.35)		-0.46 (-1.74,0.82)											
-0.68 (-2.88,1.44)		-0.88 (-0.92,0.16)													
-0.74 (-2.66,1.18)															

5.15-2 League Table of hematologic cancer



5.15-3 Funnel plot of hematologic cancer

6. References

1. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *Lancet*. 2012;380(9840):475-83.
2. Kitazawa M, Katagiri T, Suzuki H, Matsunaga S, M HY, Ikarashi T, et al. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study. *Diabetes Obes Metab*. 2021;23(3):811-21.
3. Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). *Diabetes Obes Metab*. 2014;16(7):636-44.
4. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. *Diabetologia*. 2007;50(2):259-67.
5. Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, et al. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. *Diabetes Res Clin Pract*. 2018;138:253-61.
6. Handelsman Y, Laurant B, Gantz I, Iredale C, O'Neill EA, Wei Z, et al. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Curr Med Res Opin*. 2017;33(10):1861-8.
7. Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2017;16(1):112.
8. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 2018;392(10157):1519-29.
9. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013;369(14):1327-35.
10. Perkovic V, Jardine MJ, Neal B, Bompont S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med*. 2019;380(24):2295-306.
11. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondy N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol*. 2018;6(9):691-704.
12. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. *Diabetes Care*. 2013;36(9):2508-15.
13. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. *Diabetes Care*. 2015;38(3):355-64.
14. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week

randomised, active-controlled, double-blind, phase 3 trial. *Lancet Diabetes Endocrinol.* 2014;2(9):691-700.

15. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *Jama.* 2008;299(13):1561-73.

16. Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. *J Am Geriatr Soc.* 2014;62(7):1252-62.

17. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. *BMC Med.* 2013;11:43.

18. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2019;380(4):347-57.

19. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. *Diabetes Obes Metab.* 2014;16(2):124-36.

20. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. *Diabetes Obes Metab.* 2014;16(2):159-69.

21. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. *Diabetes Care.* 2011;34(9):2015-22.

22. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. *Diabetes Care.* 2015;38(7):1218-27.

23. Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. *Lancet Diabetes Endocrinol.* 2020;8(5):377-91.

24. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet.* 2019;394(10193):121-30.

25. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. *Lancet Diabetes Endocrinol.* 2018;6(8):605-17.

26. Matthaai S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. *Diabetes Obes Metab.* 2015;17(11):1075-84.

27. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. *Diabetes Obes Metab.*

2014;16(12):1239-46.

28. Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. *Jama*. 2019;321(15):1466-80.
29. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. *Jama*. 2019;322(12):1155-66.
30. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *Jama*. 2019;321(1):69-79.
31. Kellner M, Kaltoft MS, Lawson J, Nielsen LL, Strojek K, Tabak Ö, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial. *Diabetes Obes Metab*. 2022;24(9):1788-99.
32. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. *Circulation*. 2010;121(10):1176-87.
33. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2015;373(3):232-42.
34. Yki-Järvinen H, Rosenstock J, Durán-García S, Pinnetti S, Bhattacharya S, Thiemann S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52 -week randomized, double-blind study. *Diabetes Care*. 2013;36(12):3875-81.
35. Januzzi JL, Jr., Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. *J Am Coll Cardiol*. 2017;70(6):704-12.
36. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017;377(13):1228-39.
37. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*. 2017;5(11):887-97.
38. Seino Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. *J Diabetes Investig*. 2012;3(6):517-25.
39. Lavalley-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. *Diabetologia*. 2013;56(12):2582-92.
40. Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. *Int J Clin Pract*. 2013;67(12):1267-82.
41. Müller-Wieland D, Kellner M, Cypriak K, Skripova D, Rohwedder K, Johnsson E, et al. Efficacy

and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. *Diabetes Obes Metab.* 2018;20(11):2598-607.

42. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol.* 2014;2(5):369-84.

43. Sone H, Kaneko T, Shiki K, Tachibana Y, Pfarr E, Lee J, et al. Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. *Diabetes Obes Metab.* 2020;22(3):417-26.

44. Henry RR, Staels B, Fonseca VA, Chou MZ, Teng R, Golm GT, et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. *Diabetes Obes Metab.* 2014;16(3):223-30.

45. Wang W, Nevárez L, Filippova E, Song KH, Tao B, Gu L, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial. *Diabetes Obes Metab.* 2019;21(2):234-43.

46. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). *Diabetes Care.* 2015;38(12):2241-9.

47. Nauck MA, Stewart MW, Perkins C, Jones-Leone A, Yang F, Perry C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. *Diabetologia.* 2016;59(2):266-74.

48. Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. *Diabetes Obes Metab.* 2014;16(12):1257-64.

49. Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. *Lancet Diabetes Endocrinol.* 2019;7(11):834-44.

50. Åhrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. *Lancet Diabetes Endocrinol.* 2017;5(5):341-54.

51. Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. *Lancet Diabetes Endocrinol.* 2019;7(7):528-39.

52. Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. *J Diabetes.* 2013;5(1):68-79.

53. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in

patients with type 2 diabetes. *Diabetes Obes Metab.* 2010;12(5):442-51.

54. Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. *Diabetes Care.* 2013;36(5):1067-73.

55. Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. *Diabetes Obes Metab.* 2018;20(3):530-40.

56. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab.* 2007;9(2):194-205.

57. Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. *Diabetes Care.* 2014;37(10):2723-30.

58. Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. *Diabetes Obes Metab.* 2015;17(2):179-87.

59. Schernthaner G, Durán-García S, Hanefeld M, Langslet G, Niskanen L, Östgren CJ, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). *Diabetes Obes Metab.* 2015;17(7):630-8.

60. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. *Jama.* 2015;314(7):687-99.

61. Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. *Diabetes Care.* 2019;42(12):2262-71.

62. Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. *Clin Ther.* 2015;37(8):1773-88.e1.

63. Kawamori R, Haneda M, Suzaki K, Cheng G, Shiki K, Miyamoto Y, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. *Diabetes Obes Metab.* 2018;20(9):2200-9.

64. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med.* 2015;373(22):2117-28.

65. Hollander P, Liu J, Hill J, Johnson J, Jiang ZW, Golm G, et al. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. *Diabetes Ther.* 2018;9(1):193-207.

66. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. *Diabetologia.* 2010;53(9):1838-45.

67. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and

- cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317-26.
68. Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. *Diabetes Care*. 2014;37(8):2141-8.
69. Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. *Diabetologia*. 2014;57(12):2475-84.
70. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. *Diabetes Obes Metab*. 2015;17(10):936-48.
71. Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. *Diabetes Care*. 2014;37(7):1815-23.
72. Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. *Diabetes Care*. 2015;38(3):394-402.
73. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet*. 2009;373(9662):473-81.
74. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med*. 2015;373(23):2247-57.
75. Bode B, Stenlöf K, Harris S, Sullivan D, Fung A, Usiskin K, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. *Diabetes Obes Metab*. 2015;17(3):294-303.
76. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. *Kidney Int*. 2014;85(4):962-71.
77. Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. *Diabetes Care*. 2018;41(8):1663-71.
78. Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. *Lancet*. 2015;385(9982):2057-66.
79. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. *Int J Clin Pract*. 2011;65(4):397-407.
80. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2019;381(9):841-51.
81. Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase

3a trial. *Lancet*. 2019;394(10192):39-50.

82. Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. *Cardiovasc Diabetol*. 2015;14:154.

83. Göke B, Gallwitz B, Eriksson JG, Hellqvist Å, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. *Int J Clin Pract*. 2013;67(4):307-16.

84. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet*. 2005;366(9493):1279-89.

85. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375(19):1834-44.

86. Ruff CT, Baron M, Im K, O'Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. *Nat Med*. 2022;28(1):89-95.

87. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *Int J Obes (Lond)*. 2013;37(11):1443-51.